tiprankstipranks
Advertisement
Advertisement
Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe FlySoleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
2M ago
Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
Premium
Company Announcements
Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
2M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
Neurocrine price target raised to $166 from $151 at Wedbush
PremiumThe FlyNeurocrine price target raised to $166 from $151 at Wedbush
2M ago
Soleno Withdraws EU Application for Prader-Willi Treatment
Premium
Company Announcements
Soleno Withdraws EU Application for Prader-Willi Treatment
2M ago
Neurocrine price target raised to $199 from $190 at BofA
Premium
The Fly
Neurocrine price target raised to $199 from $190 at BofA
2M ago
Hold Rating on Soleno Reflects Capped Upside Under Neurocrine Takeover Agreement
PremiumRatingsHold Rating on Soleno Reflects Capped Upside Under Neurocrine Takeover Agreement
2M ago
Soleno downgraded to Perform from Outperform at Oppenheimer
Premium
The Fly
Soleno downgraded to Perform from Outperform at Oppenheimer
2M ago
Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Premium
The Fly
Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100